166 related articles for article (PubMed ID: 9893704)
1. [Anticancer chemotherapy. Prevention of toxicity].
Chvetzoff G; Bonnotte B; Chauffert B
Presse Med; 1998 Dec; 27(39):2106-12. PubMed ID: 9893704
[TBL] [Abstract][Full Text] [Related]
2. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Hensley ML; Schuchter LM; Lindley C; Meropol NJ; Cohen GI; Broder G; Gradishar WJ; Green DM; Langdon RJ; Mitchell RB; Negrin R; Szatrowski TP; Thigpen JT; Von Hoff D; Wasserman TH; Winer EP; Pfister DG
J Clin Oncol; 1999 Oct; 17(10):3333-55. PubMed ID: 10506637
[TBL] [Abstract][Full Text] [Related]
3. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
4. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.
Links M; Lewis C
Drugs; 1999 Mar; 57(3):293-308. PubMed ID: 10193684
[TBL] [Abstract][Full Text] [Related]
5. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
6. [Anticancer chemotherapy. Prevention of complications].
Paule B; Brion N
Presse Med; 1998 Dec; 27(39):2113-9. PubMed ID: 9893705
[TBL] [Abstract][Full Text] [Related]
7. Chemoprotectants for cancer chemotherapy.
Dorr RT
Semin Oncol; 1991 Feb; 18(1 Suppl 2):48-58. PubMed ID: 1899489
[TBL] [Abstract][Full Text] [Related]
8. Use of amifostine in the therapy of osteosarcoma in children and adolescents.
Petrilli AS; Oliveira DT; Ginani VC; Kechichian R; Dishtchekenian A; Filho Wde M; Tanaka C; Dias CG; Latorre Mdo R; Brunetto AL; Cardoso H; Almeida MT; de Camargo B
J Pediatr Hematol Oncol; 2002; 24(3):188-91. PubMed ID: 11990304
[TBL] [Abstract][Full Text] [Related]
9. The potential of amifostine: from cytoprotectant to therapeutic agent.
Santini V; Giles FJ
Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
[TBL] [Abstract][Full Text] [Related]
10. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
Boven E; Verschraagen M; Hulscher TM; Erkelens CA; Hausheer FH; Pinedo HM; van der Vijgh WJ
Eur J Cancer; 2002 May; 38(8):1148-56. PubMed ID: 12008205
[TBL] [Abstract][Full Text] [Related]
11. Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients.
Fulda S; Fichtner I; Hero B; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):199-202. PubMed ID: 11464883
[TBL] [Abstract][Full Text] [Related]
12. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
13. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
14. Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine.
Budd GT; Ganapathi R; Wood L; Snyder J; McLain D; Bukowski RM
Semin Oncol; 1999 Apr; 26(2 Suppl 7):41-50. PubMed ID: 10348260
[TBL] [Abstract][Full Text] [Related]
15. Adverse effects of cytotoxics-platinum agents.
Selvaratnam G; Philips RH; Mohamed AK; Radzi A
Adverse Drug React Toxicol Rev; 1997 Aug; 16(3):171-97. PubMed ID: 9512763
[No Abstract] [Full Text] [Related]
16. Time dependent protection of amifostine from renal and hematopoietic cisplatin induced toxicity.
Asna N; Lewy H; Ashkenazi IE; Deutsch V; Peretz H; Inbar M; Ron IG
Life Sci; 2005 Mar; 76(16):1825-34. PubMed ID: 15698860
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
Selvaggi G; Belani CP
Semin Oncol; 1999 Apr; 26(2 Suppl 7):51-60. PubMed ID: 10348261
[TBL] [Abstract][Full Text] [Related]
18. A review of the use of chemoprotectants in cancer chemotherapy.
Lewis C
Drug Saf; 1994 Sep; 11(3):153-62. PubMed ID: 7811398
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study.
Kanat O; Evrensel T; Baran I; Coskun H; Zarifoglu M; Turan OF; Kurt E; Demiray M; Gonullu G; Manavoglu O
Med Oncol; 2003; 20(3):237-45. PubMed ID: 14514973
[TBL] [Abstract][Full Text] [Related]
20. Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer.
Thongprasert S; Chewaskulyong B
J Med Assoc Thai; 2004 Oct; 87(10):1162-7. PubMed ID: 15560691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
